BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mirjalili M, Shafiekhani M, Vazin A. Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen. Ther Clin Risk Manag 2020;16:617-29. [PMID: 32694915 DOI: 10.2147/TCRM.S256246] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Dęborska-Materkowska D, Kamińska D. The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients. Viruses 2021;13:1879. [PMID: 34578460 DOI: 10.3390/v13091879] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shafiekhani M, Kazemi K, Bahador A, Imanieh MH, Karimzadeh P. Pediatric liver and kidney transplantation in the era of COVID-19: a follow-up study from a tertiary referral center in Iran. BMC Surg. 2021;21:240. [PMID: 33975594 DOI: 10.1186/s12893-021-01226-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tseng HT, Wu XC, Huang CY, Shih CM, Lin YW, Lin FY. The Impact of SARS-CoV-2 Infection, and Application of Immunosuppressive Agents in Kidney Transplant Recipients Suffering from COVID-19. Pharmaceuticals (Basel) 2021;14:1054. [PMID: 34681278 DOI: 10.3390/ph14101054] [Reference Citation Analysis]
4 Dabbish AM, Yonis N, Salama M, Essa MM, Qoronfleh MW. Inflammatory pathways and potential therapies for COVID-19: A mini review. Eur J Inflamm 2021;19:205873922110029. [DOI: 10.1177/20587392211002986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Pal N, Mavi AK, Kumar S, Kumar U, Joshi MD, Saluja R. Current updates on adaptive immune response by B cell and T cell stimulation and therapeutic strategies for novel coronavirus disease 2019 (COVID-19) treatment. Heliyon 2021;7:e06894. [PMID: 33937545 DOI: 10.1016/j.heliyon.2021.e06894] [Reference Citation Analysis]
6 Rai H, Barik A, Singh YP, Suresh A, Singh L, Singh G, Nayak UY, Dubey VK, Modi G. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19. Mol Divers 2021;25:1905-27. [PMID: 33582935 DOI: 10.1007/s11030-021-10188-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Angelico R, Blasi F, Manzia TM, Toti L, Tisone G, Cacciola R. The Management of Immunosuppression in Kidney Transplant Recipients with COVID-19 Disease: An Update and Systematic Review of the Literature. Medicina (Kaunas) 2021;57:435. [PMID: 33946462 DOI: 10.3390/medicina57050435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 De Pasquale C, Pistorio ML, Veroux P, Gioco R, Giaquinta A, Privitera F, Veroux M. Quality of Life and Mental Health in Kidney Transplant Recipients During the COVID-19 Pandemic. Front Psychiatry 2021;12:645549. [PMID: 34177645 DOI: 10.3389/fpsyt.2021.645549] [Reference Citation Analysis]
9 Shafiekhani M, Shekari Z, Boorboor A, Zare Z, Arabsheybani S, Azadeh N. Bacterial and fungal co-infections with SARS-CoV-2 in solid organ recipients: a retrospective study. Virol J 2022;19:35. [PMID: 35246169 DOI: 10.1186/s12985-022-01763-9] [Reference Citation Analysis]
10 Shafiekhani M, Dehghani A, Shahisavandi M, Nabavizadeh SA, Kabiri M, Hassani AH, Haghpanah A. Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review. Ther Adv Urol 2021;13:17562872211046794. [PMID: 34603508 DOI: 10.1177/17562872211046794] [Reference Citation Analysis]
11 Shafiekhani M, Shahabinezhad F, Niknam T, Tara SA, Haem E, Mardani P, Zare Z, Jafarian S, Mirzad Jahromi K, Arabsheybani S, Moeini YS, Alavi J, Jalali SS, Salimi M, Shahriarirad R, Malekhosseini SA. Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand? Virol J 2021;18:228. [PMID: 34809657 DOI: 10.1186/s12985-021-01700-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mathew HR, Choi MY, Parkins MD, Fritzler MJ. Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. BMC Pulm Med 2021;21:173. [PMID: 34016096 DOI: 10.1186/s12890-021-01528-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Ferreira‐da‐silva R, Ribeiro‐vaz I, Morato M, Junqueira Polónia J. A comprehensive review of adverse events to drugs used in COVID‐19 patients: Recent clinical evidence. Eur J Clin Investigation. [DOI: 10.1111/eci.13763] [Reference Citation Analysis]
14 Granata S, Carratù P, Stallone G, Zaza G. mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis. Front Pharmacol 2021;12:710543. [PMID: 34497515 DOI: 10.3389/fphar.2021.710543] [Reference Citation Analysis]
15 Hage R, Steinack C, Gautschi F, Schuurmans MM. Transplant Drugs against SARS, MERS and COVID-19. Transplantology 2020;1:71-84. [DOI: 10.3390/transplantology1020007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Corvol H, de Miranda S, Lemonnier L, Kemgang A, Reynaud Gaubert M, Chiron R, Dalphin ML, Durieu I, Dubus JC, Houdouin V, Prevotat A, Ramel S, Revillion M, Weiss L, Guillot L, Boelle PY, Burgel PR. First Wave of COVID-19 in French Patients with Cystic Fibrosis. J Clin Med 2020;9:E3624. [PMID: 33182847 DOI: 10.3390/jcm9113624] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
17 Mohamed M, Smith J, Parajuli S, Garg N, Aziz F, Mandelbrot D, Djamali A, Zhong W. Successful management of T-cell mediated rejection in a recent kidney transplant recipient with COVID-19 associated severe acute respiratory syndrome. Transpl Infect Dis 2021;:e13598. [PMID: 33780103 DOI: 10.1111/tid.13598] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Negahdaripour M, Shafiekhani M, Moezzi SMI, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol 2021;99:108021. [PMID: 34352567 DOI: 10.1016/j.intimp.2021.108021] [Reference Citation Analysis]
19 Patel P, Pillai A. Liver Transplantation Services During the Time of COVID-19. J Clin Transl Hepatol 2021;9:587-91. [PMID: 34447689 DOI: 10.14218/JCTH.2021.00095] [Reference Citation Analysis]
20 Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, Dehshahri A, Vazin A. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. Int Immunopharmacol 2021;100:108162. [PMID: 34562844 DOI: 10.1016/j.intimp.2021.108162] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Singh G, Mathur U. Acute graft rejection in a COVID-19 patient: Co-incidence or causal association? Indian J Ophthalmol 2021;69:985-6. [PMID: 33727473 DOI: 10.4103/ijo.IJO_3701_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]